-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
Inhibitor Therapeutics, Inc. annual/quarterly Net Cash Provided by (Used in) Financing Activities history and growth rate from 2013 to 2023.
- Inhibitor Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2023 was -$411K, a 922% decline year-over-year.
- Inhibitor Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was -$411K, a 328% decline from 2022.
- Inhibitor Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $180K, a 2.27% increase from 2021.
- Inhibitor Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $176K, a 82.2% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)